DOCSLIB.ORG

Salicylate Induced Exacerbation of Ulcerative Colitis

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Salicylate Induced Exacerbation of Ulcerative Colitis Gut: first published as 10.1136/gut.28.5.613 on 1 May 1987. Downloaded from Gut, 1987, 28, 613-615 Case report Salicylate induced exacerbation of ulcerative colitis T K CHAKRABORTY, D BHATIA, R C HEADING, AND M J FORD From the Royal Infirmary, and Leith Hospital, Edinburgh SUMMARY The oral administration of mesalazine (5-aminosalicylic acid) resulted in the exacerba- tion of ulcerative colitis in two patients intolerant to sulphasalazine whose colitis had previously been quiescent. Although sulphasalazine intolerance is usually attributable to the sulphapyridine moiety, the possibility of salicylate sensitivity should be considered in colitic patients who fail to respond appropriately to sulphasalazine or who experience abdominal pain or diarrhoea while taking the drug. Mesalazine (Asacol, Tillotts Laboratories) is an oral an effusion necessitated the withdrawal of sulpha- 5-aminosalicylic acid coated with an acrylic based salazine. Anaemia and colitic symptoms resolved resin (Eudragit S) which is released in the terminal after six weeks hospitalisation and he was discharged ileum and colon. It has a similar clinical effect to home. Follow up over the ensuing eight years was http://gut.bmj.com/ sulphasalazine in maintaining remission in patients uneventful. with ulcerative colitis and its use has been advocated In June 1984, further hospitalisation and pred- in patients intolerant of sulphasalazine.'' Exacerba- nisolone therapy was necessitated by a relapse and tion of diarrhoea and abdominal pain in patients on review in February 1985 he was asymptomatic. receiving sulphasalazine for ulcerative colitis is un- There was no antecedent history of atopy, asthma, usual but well documented and has usually been eczema, or rhinitis. Mesalazine, 5-aminosalicylic 15 attributed to the sulphapyridine moiety. Ulcerative acid, (Asacol) 400 mg tid was then introduced. Five on September 29, 2021 by guest. Protected copyright. colitis, however, has been reported to be exacerbated days later, he developed a fever with severe bloody by salicylate therapy alone.` We report two patients diarrhoea, nausea, and vomiting. Sigmoidoscopy intolerant of sulphasalazine who developed a severe releaved the macroscopic changes of an active colitis exacerbation of ulcerative colitis after the admini- and an anal fissure. The withdrawal of mesalazine stration of 5-aminosalicylic acid. together with iv fluids resulted in a prompt clinical improvement and a normal temperature chart. Case 1 Four days later mesalazine 400 mg tid was reintro- duced and within 24 hours he had developed rigors, In June 1976, a 51 year old man (WM) was admitted temperature 39.60 C, bloody diarrhoea, nausea, to hospital with fever and bloody diarrhoea. The vomiting and an erythematous macular rash asso- diagnosis of ulcerative panproctocolitis was estab- ciated with mouth ulcers and synovitis of a wrist joint. lished on barium enema, sigmoidoscopy and rectal Antibiotic and prednisolone therapy was introduced biopsy and treatment with prednisolone 40 mg/day although he failed to improve until mesalazine was and sulphasalazine 4 g/day introduced. Severe subsequently withdrawn. recurrent anaemia in the absence of bleeding or Initial laboratory investigations revealed normal haemolysis and requiring blood transfusions, fever full blood count, liver function values and serum and the development of pleuritic chest pain with proteins. Eight days after the reintroduction of 5-aminosalicylic acid, however, the haemoglobin had fallen from 11-9 g/dl to 8-4 g/dl with a normal Addrress lor corrcspondeicc lDr M J Ford. ILcith l-ospitltl Mill Lainc. I'dinhurgh. differential count and reticulocyte count of 2%, the Rcceivced for publication 16 Septmniber 1980. serum albumin had fallen from 39 g/1 to 25 g/1 and the 613 Gut: first published as 10.1136/gut.28.5.613 on 1 May 1987. Downloaded from 614 Chakraborty, Bhatia, Heading, and Ford serum alkaline phosphatase and gamma glutamyl Discussion transferase had risen from 60 IU/l and 19 IU/l respectively to 144 IU/I and 104 IU/1. Viral and Sulphasalazine consists of sulphapyridine and bacteriological screening tests were unremarkable 5-aminosalicylic acid linked by a diazo bond. Adverse and antinuclear antibodies were not detectable. reactions to sulphasalazine are common and may be Two weeks after the introduction of prednisolone dose related or idiosyncratic in origin. Most hyper- 40 mg/day and the withdrawal of mesalazine he was sensitivity reactions, however, have been attributed asymptomatic: prednisolone therapy was gradually to the sulphapyridine moiety and include the gastro- withdrawn. Six months later, he remains asympto- intestinal side effects of nausea, vomiting, abdominal matic. pain, and diarrhoea."W" The predominantly satis- factory response of sulphasalazine intolerant patients Case 2 to 5-aminosalicylic acid supports this view.' The exacerbation of colitic symptoms in response In April 1980, a 21 year old woman (EJ) was admitted to oral or rectal sulphasalazine is unusual but well to hospital with a four month history of lower recognised.5 The similar occurrence of abdominal abdominal pain, diarrhoea, anorexia, and weight pain and bloody diarrhoea after 5-aminosalicylic acid loss. There was no antecedent history of atopy, therapy in our patients and in two patients previously asthma, eczema or rhinitis. The diagnosis of distal reported suggests that this pattern of sulphasalazine ulcerative proctocolitis was established on barium intolerance may in fact be caused by the 5-amino- enema, sigmoidoscopy and rectal biopsy. Sulpha- salicylic acid moiety of the molecule.' A total of salazine therapy, 3 g/day, was withdrawn because of 29 patients developing diarrhoea in response to nausea, vomiting, and abdominal pain. After an 5-aminosalicylic acid have been reported to date. uneventful recovery after prednisolone therapy (Tillots Laboratories-personal communication). 30 mg/day her symptoms remained well controlled The patients we describe may illustrate different over the ensuing three years on prednisolone therapy phenomena. The first case developed an exacerba- 5 mg/day. tion of colitis in association with a generalised In May 1983, she was readmitted with a severe hypersensitivity reaction to 5-aminosalicylic acid exacerbation of colitis which responded well to whereas in the second case, diarrhoea and abdominal http://gut.bmj.com/ oral and rectal prednisolone therapy. Sulphasalazine pain followed exposure to the drug without other was gradually reintroduced and for four months, evidence of hypersensitivity. Approximately one in symptoms were well controlled without prednisolone five of patients reported to Tillotts Laboratories with therapy. Nausea, vomiting, abdominal pain and diarrhoea in response to mesalazine had evidence of diarrhoea recurred, however, with sigmoidoscopic a generalised hypersensitivity reaction usually a fever evidence of active colitis. Prednisolone therapy and and/or a skin rash. A similar experience has been well the withdrawal of sulphasalazine resulted in good recorded in patients given para-aminosalicylic acid in on September 29, 2021 by guest. Protected copyright. symptomatic control. In January 1984 while on the treatment of tuberculosis. Nausea, vomiting, and prednisolone 10 mg daily, sulphasalazine desensiti- diarrhoea occur in 8% of such patients of whom less sation was attempted but nausea and diarrhoea than one third experience allergic manifestations recurred at a dosage of 500 mg daily. Because of such as fever or skin rash.'2 Fever, skin rash and a continuing mild distal proctocolitis and steroid bloody diarrhoea have been reported in a patient dependency, mesalazine 800 mg tid was introduced in given para-aminosalicylic acid." August 1984. Within 24 hours, she developed explo- Thus, although salicylate induced diarrhoea occurs sive watery diarrhoea, abdominal pain, gaseous with a spectrum of severity ranging from the non- colonic distension and pruritus. Sigmoidoscopy specific to florid hypersensitivity disorders, it is showed minimal reactive changes only; the mesala- possible that there are overlapping subpopulations in zine was withdrawn and all symptoms resolved. One whom allergic and idiosyncratic, dose related week later, mesalazine 400 mg tid was reintroduced phenomena are involved. Proctocolitis has been resulting in further abdominal pain, distension and shown to be exacerbated by acetylsalicylic acid in one watery diarrhoea necessitating its withdrawal. The atopic individual whose bowel symptoms could not full blood count, differential WBC count, serum subsequently be induced by sulphapyridine.' Non- albumin and liver function values remained normal steroidal anti-inflammatory drugs have been shown throughout. to precipitate relapse in four patients with inactive Over the ensuing three months, oral prednisolone ulcerative proctocolitis.' Studies examining analgesic was withdrawn uneventfully. By August 1985 she was ingestion in colitic patients before the onset of asymptomatic and the sigmoidoscopic appearances relapse compared with that of colitics in remission were normal. indicate a significantly higher prevalence of para- Gut: first published as 10.1136/gut.28.5.613 on 1 May 1987. Downloaded from Salicylate induced exacerbation ofulcerative colitis 615 cetamol and salicylate ingestion before relapse. Such patients unable to take sulphasalazine. Lancet 1983; ii: an association could be explained by the selective and 801. idiosyncratic inhibitory effects of non-steroidal anti- 4 Werlin
Load more

Recommended publications
  • PACKAGE LEAFLET: INFORMATION for the USER Asacol® 800Mg MR Tablets (Mesalazine) Read All of This Leaflet Carefully Before You S
    PACKAGE LEAFLET: INFORMATION FOR THE USER Asacol® 800mg MR tablets (mesalazine) Read all of this leaflet carefully before you start taking this medicine. - Keep this leaflet. You may need to read it again. - If you have any further questions, ask your doctor or pharmacist. - This medicine has been prescribed for you. Do not pass it on to others. It may harm them, even if their symptoms are the same as yours. - If any of the side effects gets serious, or if you notice any side effects not listed in this leaflet, please tell your doctor or pharmacist. In this leaflet: 1. What Asacol 800mg MR tablets are and what they are used for 2. Before you take Asacol 800mg MR tablets 3. How to take Asacol 800mg MR tablets 4. Possible side effects 5. How to store Asacol 800mg MR tablets 6. Further information 1. WHAT ASACOL 800MG MR TABLETS ARE AND WHAT THEY ARE USED FOR Asacol 800mg MR tablets contain the active substance mesalazine (also known as 5- aminosalicylic acid) which is an anti-inflammatory drug used in the treatment of: • Ulcerative colitis - a disease of the large bowel (colon) and back passage (rectum) in which the lining of the bowel becomes inflamed (red and swollen). Symptoms can include rectal bleeding, frequent diarrhoea and abdominal pain. Asacol 800mg MR tablets act locally in the colon to reduce inflammation and can also prevent further episodes (flares) of ulcerative colitis. • Crohn’s ileo-colitis – a disease affecting the small bowel (terminal ileum) and colon in which the lining of the bowel becomes swollen and sore.
    [Show full text]
  • Download This PDF File
    Chimica Analitica ANA-KN-01 Functionalized carbon nanostructures and metal nanoparticles: from effective charge propagation to enhancement of electrocatalytic, photoelectrocatalytic and bioelectrocatalytic properties Pawel J. Kulesza Department of Chemistry, University of Warsaw, Pasteura 1, PL-02-093 Warsaw, Poland * [email protected] Of particular interest to the preparation of advanced materials is synthesis and characterization of carbon nanostructures (e.g. nanotubes) and noble metal nanoparticles, their stabilization (e.g. through self-assembly), as well as organization into two-dimensional arrays and controlled fabrication (e.g. through the sequential attraction) into three-dimensional network films. They can form nanosized materials with well-defined composition, structure and thickness. The interfaces can be also highly functionalized, and they can exhibit specific catalytic or unique electronic, charge storage, optical and sensing properties. We explore here the ability of inorganic structures to stabilize and derivatize metal and carbon nanostructures. Among inorganic systems, polyoxometallates of molybdenum and tungsten are attractive since they can not only adsorb irreversibly on solid surfaces but also exhibit reversible stepwise multielectron transfer reactions. The concept of the layer-by-layer formation of hybrid (organic-inorganic) assemblies composed of anionic polyoxometallate-protected carbon nanotubes (or metal nanoparticles) and ultra-thin films of positively charged conducting polymers (e.g. such as polyaniline or PEDOT) will be described and discussed here. The resulting novel composite materials have been fabricated as thin or moderately thick (µm level) films on electrode surfaces. As evidenced from STM and scanning electron microscopy, their morphology is still granular but the structure is fairly dense. Further, they are characterized by fast dynamics of charge propagation.
    [Show full text]
  • Testing Kits for Kinesiologists & Natural Therapists
    Testing Kits for Kinesiologists & Natural Therapists The kits come in easy seal bags and boxes are available separately for storage if required (see below). Postage will range from $7.00 to $13.00 ($12 to $26 for Express). The prices of these kits may change from time to time. Please check before or when ordering as to any prices changes. Individual vials may be purchased from kits for $17 each (or $13 each for 7 or more). Other single vials & update vials - see pages back of manual This manual is available at $29.00 plus $7.00 postage. With kit purchases it is available at a basic price of $19.00. After an initial purchase, any updated or later editions can be purchased at $15.00 plus $7.00 postage. Testing Kit Boxes & Empty Vials: Test Kit Box for 50 Vials (plastic box - vials upright): $13.00 or $10.00 with kits Test Kit Box for 100 Vials (plastic box - vials upright): $17.00 or $14.00 with Kits Test Kit Box for 72 vials (flat cardboard box with foam inlay – vials lay flat): $42 or $35 with kits Empty Vials for Liquids: 8 x 40 mm glass vial with plastic top: $6.00 per 10 vials or $52.00 per 100 pack. Empty Vials for Solids: 10 x 40mm glass vial with plastic top: $8.00 per 10 vials or $69.00 per 100 pack Pathology & Histology Testing Kits A Range of Kinesiological Testing Kits for Anatomy & Pathologies of the Body Organs & Systems (contents lists included in this manual) see contents page 3 Flower Essences We supply a variety of Flower Essences, and other types of Essences, plus accessories.
    [Show full text]
  • Salofalk®) in an Open Study of 20 Patients with Ankylosing Spondylitis
    Efficacy and Safety of Mesalazine (Salofalk®) in an Open Study of 20 Patients with Ankylosing Spondylitis J. CHRISTIAAN van DENDEREN, IRENE E. van der HORST-BRUINSMA, P. DICK BEZEMER, and BEN A.C. DIJKMANS ABSTRACT. Objective. Mesalazine (Salofalk®) was found to be effective and showed low toxicity in patients with inflammatory bowel disease. The association of gut lesions and spondyloarthropathy (SpA) is well known and we studied the efficacy and safety of a relatively high dose of mesalazine in patients with ankylosing spondylitis (AS). Methods. In an open study, mesalazine (3–4 g/day) was prescribed for 24 weeks to 20 patients (aged 18–70 yrs) with active AS, defined as the presence of at least one clinical criterion (morning stiff- ness > 30 min, peripheral synovitis, enthesopathy, or pain score > 2 on a visual analog scale of 10 cm) and one laboratory criterion [erythrocyte sedimentation rate (ESR) > 20 mm/h or C-reactive protein (CRP) > 20 mg/l]. Data on toxicity and disease activity variables (ESR, CRP, BASDAI, BASFI, BASMI, global assessment, and joint count) were obtained at baseline and after 4, 12, and 24 weeks, and analyzed on an intention-to-treat basis. Results. Study patients had a mean age of 41 years, with mean disease duration of 7.9 years and a mean ESR at baseline of 29 mm/h. After a mean of 9.3 weeks (range 2–22), 8 of the 20 patients prematurely stopped the medication because of adverse effects, mainly gastrointestinal complaints. Twelve patients completed the 24 weeks of the study using a mean dose of 3.2 g/day (range 1–4) mesalazine.
    [Show full text]
  • Development of Mesalazine Microspheres for Colon Targeting
    International Journal of Applied Pharmaceutics ISSN- 0975-7058 Vol 9, Issue 4, 2017 Original Article DEVELOPMENT OF MESALAZINE MICROSPHERES FOR COLON TARGETING KATTA RAJESH, R. DEVESWARAN *, S. BHARATH, B. V. BASAVARAJ Department of Pharmaceutics, Faculty of Pharmacy, M. S. Ramaiah University of Applied Sciences, Bangalore 560054 Email: [email protected] Received: 28 Jan 2017, Revised and Accepted: 14 Jun 2017 ABSTRACT Objective: The present work was aimed at preparation of mesalazine microspheres by a non-aqueous solvent evaporation method using eudragit S 100 and eudragit L 100 as pH dependent polymers for colon targeting. Methods: The ratio of drug to polymer was varied and the effect of formulation variables revolutions per minute (RPM) (1000, 1500, 2000 and 2500) and concentration of span 80 (1%, 1.5%, 2% and 2.5%) were studied. Prepared microspheres were evaluated for particle size, percent drug entrapment, granular analysis, in vitro drug release studies, Fourier transformed infrared spectroscopy (FT-IR) Differential Scanning Calorimetry (DSC), X-ray diffraction (XRD) and scanning electron microscopy (SEM) studies. Results: Particle size has decreased and percent drug entrapment had increased with increase in RPM in all formulations. When the span 80 concentration increased, the particle size of the microsphere formulations increased and percent drug entrapment decreased in eudragit S 100 microspheres; whereas in eudragit L 100 microspheres, as the concentration of span 80 increased, the particle size of the microsphere formulations decreased. The prepared microspheres sustained the drug release over a period of 12 h. Conclusion: Thus eudragit S 100 and eudragit L 100 microspheres could constitute a promising approach for colon-specific and sustained delivery of mesalazine for the treatment of inflammatory bowel disease.
    [Show full text]
  • Recent Advances in Mesalamine Colonic Delivery Systems Mohammad F
    Bayan and Bayan Future Journal of Pharmaceutical Sciences (2020) 6:43 Future Journal of https://doi.org/10.1186/s43094-020-00057-7 Pharmaceutical Sciences REVIEW Open Access Recent advances in mesalamine colonic delivery systems Mohammad F. Bayan* and Rana F. Bayan Abstract Background: Increased attention has been focused on the continuous development and improvement of mesalamine colonic specific delivery systems, for the effective treatment of inflammatory bowel diseases; thus enhancing therapeutic efficacy and reducing potential side effects. Mesalamine is a class IV drug, according to the Biopharmaceutics Classification System, used usually to treat inflammation associated with colon related diseases such as Crohn’s disease and ulcerative colitis. Main text An ideal colon targeting system aims to deliver a therapeutic agent, selectively and effectively, to the colon. This system should ideally retain the drug release in the upper GI tract (stomach and small intestine); while trigger the drug release in the colon. Several approaches have been used to fabricate formulations to achieve a colon specific delivery of mesalamine such as; time dependent, pH responsive, enzymatic/microbial responsive and ultrasound mediated approaches. This overview outlines the recent advances in mesalamine-colon delivery approaches for the potential treatment of ulcerative colitis and Crohn’ disease. Conclusion: A combined pH-time dependent delivery system can improve mesalamine colonic drug delivery via employing carriers capable of retarding mesalamine release in the stomach and delivering it at predetermined time points after entering the intestine. The existence of specific enzymes, produced by various anaerobic bacteria present in the colon advocates the advantage of designing enzyme sensitive systems and combining it with pH- time dependent system to improve mesalamine colonic delivery.
    [Show full text]
  • Physicochemical Compatibility Investigation of Mesalazine and Folic Acid Using Chromatographic and Thermoanalytical Techniques
    pharmaceuticals Article Physicochemical Compatibility Investigation of Mesalazine and Folic Acid Using Chromatographic and Thermoanalytical Techniques Mario-Livio Jeliˇci´c,Edvin Brusaˇc , Daniela Amidži´cKlari´c , Biljana Nigovi´c , Sabina Keser and Ana Mornar * Faculty of Pharmacy and Biochemistry, University of Zagreb, A. Kovaˇci´ca1, 10000 Zagreb, Croatia; [email protected] (M.-L.J.); [email protected] (E.B.); [email protected] (D.A.K.); [email protected] (B.N.); [email protected] (S.K.) * Correspondence: [email protected]; Tel.: +385-1-481-8288 Received: 16 July 2020; Accepted: 7 August 2020; Published: 8 August 2020 Abstract: Inflammatory bowel disease is a common name for Crohn’s disease and ulcerative colitis. These inflammatory states cause damage in the sidewalls of the gastrointestinal tract, resulting in malabsorption of food and vitamins. Folic acid (Vitamin B9) is often associated with inflammatory bowel diseases since reduced overall folate concentration in the human body may lead to the development of colorectal cancer and megaloblastic anaemia. However, its deficiency is easily compensated by taking an additional folic acid pill during regular therapy. At the moment, there are no studies that have examined the compatibility of folic acid with 5-aminosalicylate drugs used in the treatment of inflammatory bowel diseases. In this work, differential scanning calorimetry, forced degradation studies, isothermal stress testing and dissolution stability testing were used to determine the stability of folic acid and one of the most commonly used 5-aminosalicylates, mesalazine, when present in the same solution or blend. To monitor the assay of folic acid, mesalazine and nine of its related impurities, a single HPLC method was developed.
    [Show full text]
  • Mesalazine Improves Replication Fidelity in Cultured Colorectal Cells
    Priority Report Mesalazine Improves Replication Fidelity in Cultured Colorectal Cells Christoph Gasche,1 Ajay Goel,2 Loki Natarajan,3 and C. Richard Boland2 1Department of Medicine 4, Division of Gastroenterology and Hepatology, Medical University Vienna, Vienna, Austria; 2Baylor University Medical Center, Dallas, Texas; and 3Biostatistics, Cancer Center, University of California, San Diego, California Abstract cancer is, however, derived from aspirin, acetylsalicylic acid, Epidemiologic studies indicate that mesalazine has chemo- which is structurally similar to mesalazine. The molecular preventive effects in inflammatory bowel disease–associated mechanisms by which aspirin and other nonsteroidal anti- colorectal cancer. Most of our general understanding of inflammatory drugs exert chemopreventive effects in colon chemoprevention in colorectal cancer is, however, derived cancer are complex and a matter of ongoing debate. Besides from aspirin, which is structurally similar to mesalazine. the well-established effects on cyclooxygenase, aspirin and Herein we determined the influence of aspirin and mesala- nonsteroidal anti-inflammatory drugs are thought to mediate their antineoplastic properties by other mechanisms including zine on replication fidelity in cultured colorectal cells. Flow n cytometry was used for quantitation of mutation rates at a inhibition of nuclear factor B (4). Another possible target for the activity of nonsteroidal anti-inflammatory drugs is the (CA)13 microsatellite in HCT116 cells (mismatch repair deficient) and HCT116+chr3 cells (mismatch repair profi- improvement of DNA replication. The fidelity of DNA replication cient) that had been stably transfected with pIREShyg2- is a product of polymerase accuracy, its proofreading activity, EGFP/CA13, an enhanced green fluorescence protein–based and the proficiency of the postreplicational mismatch repair plasmid, and cultured in the absence or presence of various system (5).
    [Show full text]
  • (5-ASA): a Unique Anti-Inflammatory Salicylate
    l ch cina em di is e tr Abdu-Allah et al., Med chem (Los Angeles) 2016, 6:5 M y Medicinal chemistry DOI: 10.4172/2161-0444.1000361 ISSN: 2161-0444 Review Article Open Access 5-Aminosalyclic Acid (5-ASA): A Unique Anti-Inflammatory Salicylate Hajjaj H Abdu-Allah1, Abdel-Nasser A El-Shorbagi1,2*, Samia G Abdel-Moty1, Raafat El-Awady2 and Abdel-Alim M Abdel-Alim1 1Department of Pharmaceutical Organic Chemistry, Faculty of Pharmacy, Assiut University, Assiut 71526, Egypt 2Sharjah Institute for Medical Research, College of Pharmacy, University of Sharjah, Sharjah-27272, UAE Abstract Salicylic acid (SA) derivatives are widely used for treatment of various diseases. Acetylsalicylic acid represents the most widely used drug in the world, 4-Aminosalicylic acid (4-ASA) was historically used as a systemic anti- tuberculosis drug as well as diflunisal is a strong pain killer and antipyretic. 5-Aminosalicylic acid (5-ASA) which had been synthesized at the end of 19th century and employed first for the production of azo dyes, was then identified as a very valuable medicinal agent as well as part of many biologically active agents. 5-ASA is not metabolized to salicylic acid for pharmacological activity. It is not considered a true salicylate. In contrary to other salicylates, 5-ASA doesn’t induce upper gastrointestinal (GI) side effects. Moreover, It was found, especially, useful for treatment of inflammatory bowel diseases (IBD). It is unique among salicylates and has a broad specrum of biological activities including, anti-inflammatory, analgesic, neuroprotective and antitumor. Since we are interested in this compound and its derivatives, we prepared this review to give insight into its chemistry, anti-inflammatory activity, in particular, for treatment of IBD.
    [Show full text]
  • Formulation of Ketorolac Tromethamine for Controlled Release in Gastrointestinal and Colonic Delivery System
    Indonesian J. Pharm. Vol. 29 No. 2 : 49 – 59 Research Article ISSN-p : 2338-9427 DOI: 10.14499/indonesianjpharm29iss2pp49 Formulation of Ketorolac Tromethamine for Controlled Release in Gastrointestinal and Colonic Delivery System Md. Amzad Hossain1, Swapon Kumar Shill2, Shakhawat Hasan Khan2, S. M. Moazzem Hossen3 and Mohammad Nasir Uddin2* 1Department of Pharmacy, ABSTRACT University Science and A suitable matrix system of ketorolac tromethamine (KTR) Technology Chittagong, formulation has been developed with the aim of increasing the Bangladesh. contact time, achieving controlled release, reducing the 2 Department of Chemistry, frequency of administration, improving patient compliance. In University of Chittagong, this concern an enteric-coated KTR matrix tablet intended for Chittagong-4331, specific delivery of drugs to the colon by combining the use of a Bangladesh. time dependent core with a pH-sensitive film coating. Eudragit 3Department of Pharmacy, L100, with a threshold pH 7, was selected as coating material. University of Chittagong, New formulation is proved to be noble as to KTR delivery through Chittagong-4331, both gastrointestinal and colonic system. New formulation is Bangladesh. considered to reduce gastrointestinal side effects and achieve Submitted: 08-02-2018 high local drug concentration at the afflicted site in the gastro- Revised: 20-03-2018 intestine and colon. Accepted: 16-04-2018 Key words: Drug Formulation, Ketorolactromethamine, gastrointestinal and colonic delivery system, HPLC analysis *Corresponding author M. Nasir Uddin *Corresponding author Email: [email protected] INTRODUCTION postoperative cancer pain and in the treatment The magnitude of these fluctuations due of migraine pain (Andrade et al., 1994). As the to the administration of drugs in conventional biological half-life of KTR is 4–6 h frequent dosage forms depends on the rates of dosing is necessary to sustain the action of drug absorption, distribution and elimination and to alleviate pain in postoperative patients.
    [Show full text]
  • The Carnivore Code Paul Saladino, M.D
    By dag Forssell, Jan 23, 2021 Comments: [email protected] Salicylates as discussed in The Carnivore Code Paul Saladino, M.d. CHAPTER 5: OF UNICORNS AND FAIRY TALES PERHAPSCHAPTER MORE THAN 6: ATTACKany other plant OF molecule,THE OXALATES polyphenols have become associated with the term “superfoods.” They are often dubbed “antioxidants,” and we are told to consume as much of them as possible. It seemsIN THE that FREQUENTLYPREVIOUS every day, two another chapters, ASKEDcompany we talked comes QUESTIONS about out plant with defense a supposedly chemicals magicalthat can supplement, have damaging juice, effectsor powder in ourwith bodiesbold claimsbecause of they’redecreased not inflammationcompatible with and ourlongevity human as operating it touts itssystem. robust In polyphenol this chapter, content. we’re Let’sgoing WHEN I STARTED writing this book, I knew that I would never be able to talkto talkabout about what apolyphenols molecule that actually is produced are and inwhy small we’ve quantities been told as they a waste are address every single possible question that arose from it—that’s what my 2223-2228.Textgoodproduct excerpted for ofus. human Then from metabolismwe’ll thesediscuss but chapters, why occurs I’m in going veryfollowed largeto take amounts bythe text,radically in some tables, next books are for. In an effort to be as comprehensive as possible, 38. Lawrence,contraryplants, andviewpointJ. R.,can Peter,cause that serious theirR., Baxter,purported pain, kidney G. benefits J., stones, Robson, are andnothing other J., moreGraham, issues than when the A. it B., & however,and I am comments including this copied section from to address the manyweb commonlypage listed asked stuffaccumulates of imagination, in our body.
    [Show full text]
  • PENTASA® Is Addictive
    ® Ask your doctor if you have Before you start to take it PENTASA any questions about why Mesalazine this medicine has been Tell your doctor if you have prescribed for you. Your allergies to any other Prolonged release tablets doctor may have prescribed it medicines, foods, for another reason. preservatives or dyes. Consumer Medicine There is no evidence that Tell your doctor if you have Information PENTASA® is addictive. or have had any of the following medical What is in this leaflet It is available only with a conditions: doctor’s prescription. a known allergy to This leaflet answers some It is not expected to affect your PENTASA®, common questions about ability to drive a car or operate sulphasalazine or aspirin- ® PENTASA . machinery. like medicines, or any of It does not contain all the the ingredients listed at the available information. It does Before you take end of this leaflet not take the place of talking to ® a kidney or liver problem your doctor or pharmacist. PENTASA a bleeding disorder a history of asthma Please read this leaflet before When you must not take it ® you start using PENTASA . Tell your doctor if you are Do not take PENTASA® if pregnant or plan to become All medicines have risks and you have an allergy to: pregnant or are breast- benefits. Your doctor has feeding. weighed the risks of you using any medicine containing ® Your doctor can discuss with PENTASA against the mesalazine or aspirin-like you the risks and benefits benefits they expect it will have medicines involved. PENTASA® should for you.
    [Show full text]